Table 2.
Demographic data and clinical characteristics between two groups.
| No. (%), mean ± SD or median (IQR) | |||
|---|---|---|---|
| HIV-NCI (n = 33) | HIV-control (n = 33) | P-value | |
| Average age (year) | 61.16 ± 6.88 | 59.41 ± 5.41 | 0.25a |
| Gender (male, %) | 32 (97.0) | 30 (90.9) | 0.29b |
| Years of education (n[%]) | 0.41b | ||
| Primary school and below | 1 (3.0) | 3 (9) | – |
| Junior school | 20 (60.6) | 17 (51.5) | – |
| Senior school | 10 (30.3) | 8 (24.2) | – |
| Undergraduate and above | 2 (6.0) | 5 (15.1) | – |
| MMSE score | 22.26 ± 2.98 | 26.55 ± 1.30 | 0.002a |
| IHDS score | 7.12 ± 1.82 | 9.27 ± 1.06 | 0.003a |
| PSQI score | 8.03 ± 3.68 | 7.40 ± 3.03 | 0.44a |
| SAS score | 41.88 ± 7.26 | 40.15 ± 8.06 | 0.36a |
| HIV-infected related variables | |||
| Time since HIV diagnosis (years) | 5.58 (3.42–7.75) | 5.43 (3.39–7.93) | 0.83c |
| Duration of ART (years) | 4.89 (3.16–7.34) | 5.29 (3.09–7.41) | 0.94c |
| AIDS (v.s. HIV, n[%]) | 13 (39.4) | 10 (33.3) | 0.47b |
| Nadir CD4 count, cells/μL | 160 (72–279) | 156 (57–255) | 0.48c |
| Current CD4 count, cells/μL | 453 (306–640) | 432 (333–620) | 0.75c |
NCI neurocognitive impairment, wNCI without neurocognitive impairment, MMSE minimum mental state examination, IHDS International HIV Dementia Scale, PSQI Pittsburgh Sleep Quality Index, SAS Self-rating Anxiety Scale, ART antiretroviral therapy, AIDS refer to the AIDS stage of HIV infection, SD standard deviation.
aTwo independent-sample test.
bChi-square test.
cWilcoxon rank sum test.